Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?-Reference-Cited by-同舟云学术

Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?

Published:2021-09-25 Issue:11 Volume:21 Page:1229-1235
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Gabay Carolina¹,Russo Alessandro²,Raez Luis E.³^ORCID,Rolfo Cervetto Christian⁴

Affiliation:

1. Angel H. Roffo Cancer Institute, University of Buenos Aires, Buenos Aires, Argentina

2. Medical Oncology Unit, A.O Papardo, Messina, Italy

3. Memorial Cancer Institute/Memorial Healthcare System, Herbert Wertheim College of Medicine/Florida International University, Pembroke Pines, FL, USA

4. Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & Icahn School of Medicine, Mount Sinai, New York, NY, USA

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1982387

Reference31 articles.

1. Postoperative Adjuvant Systemic Therapy in Completely Resected Non–Small-Cell Lung Cancer: A Systematic Review

2. EGFR Mutations in Latinos From the United States and Latin America

3. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

4. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of crucial anoikis-related genes as novel biomarkers and potential therapeutic targets for lung adenocarcinoma via bioinformatic analysis and experimental verification;Aging;2024-02-09

2. Identification of Potential Key Genes and Prognostic Biomarkers of Lung Cancer Based on Bioinformatics;BioMed Research International;2023-01-18

3. Chemopreventive role of Tin oxide-Chitosan-Polyethylene glycol-Crocin nanocomposites against Lung cancer: An in vitro and in vivo approach;Process Biochemistry;2022-09

4. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC;Targeted Oncology;2022-05

5. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy;MedComm;2021-12